SAN DIEGO: ClearNote Health raises $52 million in Series D funding to advance its AI platform for early detection of the deadliest cancers.
The company applies epigenomic analysis combined with AI to identify cancers earlier. Its platform targets diseases like pancreatic and liver cancer with poor survival rates. Early detection dramatically improves outcomes across most cancer categories medically.
ClearNote’s technology reads epigenetic signatures in blood samples rather than just DNA mutations. The approach catches cancers at stages traditional screening tools often miss entirely. AI models trained on patient data identify subtle patterns invisible to manual review.
Late-stage cancer diagnosis remains one of the costliest failures in modern medicine. Pancreatic cancer kills more than 90% of patients within five years globally. Detection at earlier stages could transform survival rates dramatically across patient populations.
The Series D arrives amid surging investor interest in AI-driven medical diagnostics. Aidoc raised $150 million on May 11 for clinical imaging AI expansion. Isomorphic Labs closed $2.1 billion for AI drug discovery the following day.
Hospital procurement teams increasingly treat AI diagnostic tools as essential infrastructure. Regulatory pathways at the FDA and overseas continue expanding for AI medical devices. Clinical evidence requirements remain rigorous but no longer represent insurmountable barriers.
ClearNote competes in a crowded early cancer detection category currently. Grail, Exact Sciences, and Freenome all push competing multi-cancer screening tests. Each company races to build clinical evidence and physician adoption at scale.
The fresh capital funds expanded clinical validation studies and commercial launch activities. ClearNote also plans to deepen partnerships with health systems and oncology networks. New tests target additional cancer types beyond the company’s current focus areas.
Customer counts, revenue figures, and test pricing remain undisclosed at this stage.
Previous
